Skip to search formSkip to main contentSkip to account menu

EVP-6124

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Discovery of fused heterocyclic carboxamide derivatives as novel α7-nAChR agonists: Synthesis, preliminary SAR and biological evaluation.
2017
2017
Nicotine and symptoms of schizophrenia: the 2017 picture
The tendency of people who suffer with schizophrenia to consume large amounts of cigarettes and to extract more nicotine from… 
2016
2016
Alpha-7 nicotinic agonist improves cognition in schizophrenia
ABSTRACT FROM: Keefe RS, Meltzer HA, Dgetluck N, et al . Randomized, double-blind, placebo-controlled study of encenicline, an α7… 
2015
2015
Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
2015
2015
Continuous infusion of the α7 nicotinic acetylcholine receptor agonist EVP-6124 produces no signs of tolerance at memory-enhancing doses in rats: a pharmacokinetic and behavioral study.
We investigated whether the effects of acutely administered EVP-6124, an α7 nicotinic acetylcholine receptor (α7 nAChR) agonist… 
2015
2015
Development of Automated Patch Clamp Assay for Evaluation of α7 Nicotinic Acetylcholine Receptor Agonists in Automated QPatch-16.
The α7 nicotinic acetylcholine receptor (α7 nAChR) is an important and challenging target for drug discovery in the area of… 
Review
2014
Review
2014
Nicotinic Acetylcholine Receptors Are Potential Therapeutic Targets of Schizophrenia
Schizophrenia is a chronic, severe, and disabling mental illness affecting approximately 2.5 million Americans. Despite enormous… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)